利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.025 秒)

    1,2,4-benzothiadiazine oxide derivatives
    3.
    发明授权
    1,2,4-benzothiadiazine oxide derivatives 失效
    1,2,4-苯并噻二嗪氧化物衍生物

    公开(公告)号：US4612311A

    公开(公告)日：1986-09-16

    申请号：US772501

    申请日：1985-09-04

    申请人： Hubert Barth ,  Johannes Hartenstein ,  Gerhard Satzinger ,  Edgar Fritschi ,  Hartmut Osswald ,  Gerd Bartoszyk

    发明人： Hubert Barth ,  Johannes Hartenstein ,  Gerhard Satzinger ,  Edgar Fritschi ,  Hartmut Osswald ,  Gerd Bartoszyk

    IPC分类号： A61K31/395 ,  A61P25/24 ,  A61P25/26 ,  C07D513/04 ,  A61K31/54

    CPC分类号： C07D513/04

    摘要： 1,2,4-Benzothiadiazine oxide derivatives of the general Formula I ##STR1## in which R.sup.1 represents an unsubstituted or substituted aryl radical;R.sup.2 and R.sup.5, which may be the same or different, and represent hydrogen, halogen, or a nitro group, andR.sup.3 represents a hydrogen atom or a hydroxy radical, an alkyl, alkoxy alkyl or alkoxy carbonyl radical with up to four carbon atoms, unsubstituted or substituted by halogen, hydroxy, amino, alkyl amino or dialkyl amino radicals, or a phenyl radical, unsubstituted or substituted by halogen,are described as having anxiolytic effects on the central nervous system.

    摘要翻译： 其中R 1表示未取代或取代的芳基的通式I（I）的1,2,4-苯并噻二嗪氧化物衍生物; R 2和R 5可以相同或不同，表示氢，卤素或硝基，R 3表示氢原子或羟基，具有至多4个碳原子的烷基，烷氧基烷基或烷氧基羰基， 被卤素，羟基，氨基，烷基氨基或二烷基氨基取代或被未取代或被卤素取代的苯基被描述为对中枢神经系统具有抗焦虑作用。

    1,6-naphthyridine derivatives useful for treating diseases of the blood vessels
    5.
    发明授权
    1,6-naphthyridine derivatives useful for treating diseases of the blood vessels 失效
    可用于治疗血管疾病的1,6-萘啶衍生物

    公开(公告)号：US4760081A

    公开(公告)日：1988-07-26

    申请号：US7686

    申请日：1987-01-28

    申请人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Hartmut Osswald ,  Gunter Weinheimer ,  Edgar Fritschi

    发明人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Hartmut Osswald ,  Gunter Weinheimer ,  Edgar Fritschi

    IPC分类号： C07D213/80 ,  C07D471/04 ,  A61K31/435

    CPC分类号： C07D213/80 ,  C07D471/04

    摘要： The present invention describes 1,6-naphthyridine derivatives of the general formula: ##STR1## wherein R.sup.1 is an unsubstituted or substituted aromatic or heteroaromatic ring, R.sup.2 is a straight-chained or branched alkyl radical containing up to four carbon atoms or a benzyl radical, R.sup.3 is a hydrogen atom, a straight-chained or branched alkyl radicals or an alkoxycarbonyl radical containing up to four carbon atoms, R.sup.4 is a straight-chained or branched alkyl radical containing up to four carbons and R.sup.5 is a carboxyl group or a straight-chained, branched or cyclic alkoxycarbonyl radical which contains up to 17 carbon atoms and optionally also contains an oxygen, sulphur or nitrogen atom; as well as the pharmacologically acceptable salts thereof, which are useful for treating diseases of the blood vessels.

    摘要翻译： 本发明描述了以下通式的1,6-萘啶衍生物：其中R 1是未取代或取代的芳族或杂芳族环，R 2是含有至多4个碳原子的直链或支链烷基或苄基 R3是氢原子，直链或支链烷基或含有最多四个碳原子的烷氧基羰基，R4是含有至多四个碳的直链或支链烷基，R5是羧基或直链 链，支链或环状的烷氧基羰基，其含有至多17个碳原子，并且任选地还含有氧，硫或氮原子; 以及其药理学上可接受的盐，其可用于治疗血管疾病。

    3-aryl-3-pyrroline derivatives
    6.
    发明授权
    3-aryl-3-pyrroline derivatives 失效
    3-芳基-3-吡咯啉衍生物

    公开(公告)号：US4626546A

    公开(公告)日：1986-12-02

    申请号：US637351

    申请日：1984-08-03

    申请人： Gerhard Satzinger ,  Karl Mannhardt ,  Johannes Hartenstein ,  Manfred Herrmann ,  Edgar Fritschi ,  Wolfgang Steinbrecher

    发明人： Gerhard Satzinger ,  Karl Mannhardt ,  Johannes Hartenstein ,  Manfred Herrmann ,  Edgar Fritschi ,  Wolfgang Steinbrecher

    IPC分类号： A61K31/40 ,  A61P9/08 ,  A61P9/10 ,  C07D207/20

    CPC分类号： C07D207/20

    摘要： The invention is concerned with partially new compounds of the general formula ##STR1## wherein R.sup.1 is a hydrogen atom or an alkyl group with up to four carbon atoms and R.sup.2 a substituted phenyl radical and the pharmacologically acceptable salts thereof.The compounds can be prepared according to known procedures and show surprisingly a cardiovascular efficacy. They are capable of decompensating cardiac insufficiencies to a large extent. In addition to the new compounds, claim is also made for pharmaceutical compositions which contain compounds according to the general formula and their application for controlling cardiac and vascular diseases.

    摘要翻译： 本发明涉及通式“IMAGE”的部分新化合物，其中R 1为氢原子或具有至多4个碳原子的烷基，R 2为取代的苯基及其药理学上可接受的盐。 这些化合物可以根据已知的方法制备并令人惊奇地显示出心血管功能。 它们能够在很大程度上失代偿心脏功能不全。 除了新化合物之外，还提出了含有根据通式的化合物及其用于控制​​心脏和血管疾病的应用的药物组合物。

    Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
    10.
    发明授权
    Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis 失效
    使用1,6-萘啶酮衍生物治疗肺血栓形成

    公开(公告)号：US4698341A

    公开(公告)日：1987-10-06

    申请号：US753758

    申请日：1985-07-11

    申请人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Manfred Herrmann ,  Edgar Fritschi ,  Horst-Dietmar Tauschel ,  Bernd Wagner ,  Gunter Wolf

    发明人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Manfred Herrmann ,  Edgar Fritschi ,  Horst-Dietmar Tauschel ,  Bernd Wagner ,  Gunter Wolf

    IPC分类号： C07D211/90 ,  C07D471/04 ,  A61K31/455 ,  A61K31/535

    CPC分类号： C07D471/04 ,  C07D211/90

    摘要： New 1,6-naphthyridinone derivatives of the formula I ##STR1## are herein described wherein R.sup.1 represents an unsubstituted or substituted aromatic or heteroaromatic ring;R.sup.2 is hydrogen, a straight-chained or branched alkyl, alkoxyalkyl, or a substituted or unsubstituted aminoalkyl group with up to ten carbon atoms;R.sup.3 is hydrogen, a straight-chained or branched alkyl group, or an alkoxycarbonyl radical with up to four carbon atoms;R.sup.4 is hydrogen, or a morpholinoethyl group;R.sup.5 is a straight-chained or branched alkyl group with up to four carbon atoms, or an amino group; andR.sup.6 is a carboxyl group, or an alkyl- or alkyloxyalkyl carbonyl radical, containing up to 12 carbon atoms and optionally interrupted by an oxygen, sulphur, or nitrogen atom;as well as optionally the pharmacologically acceptable salts thereof; processes for the preparation of these derivatives and their use in the control of vascular diseases.

    摘要翻译： 本文描述了式I（I）的新的1,6-萘啶酮衍生物，其中R 1表示未取代或取代的芳族或杂芳族环; R2是氢，直链或支链烷基，烷氧基烷基或具有至多10个碳原子的取代或未取代的氨基烷基; R3是氢，直链或支链烷基或具有至多四个碳原子的烷氧基羰基; R4是氢或吗啉代乙基; R5是具有至多4个碳原子的直链或支链烷基或氨基; 并且R 6是含有至多12个碳原子并任选被氧，硫或氮原子中断的羧基或烷基 - 或烷氧基烷基羰基; 以及任选地其药理学上可接受的盐; 这些衍生物的制备方法及其在血管疾病控制中的应用。